CurrentUnitedHealthcarePolicy 2025D0078G

Subcutaneous Implantable Naltrexone Pellets

Defines UnitedHealthcare coverage stance for compounded implantable naltrexone pellets used to treat opioid dependence; applies to providers and members in the specified jurisdiction and excludes FDA-approved Vivitrol® injectable therapy.

Policy Summary

PayerUnitedHealthcare

PolicySubcutaneous Implantable Naltrexone Pellets

Policy CodePolicy 2025D0078G

Change TypeTemplate updateroutine review

Effective DateJan 1, 2025

Next Review Date

Key ActionDo not submit claims for compounded implantable naltrexone pellets as they are considered not proven and not medically necessary and are subject to denial.

SourceLink

POLICY UPDATE CHANGES

Updated Benefit Considerations section as part of a template update.

Routine review; archived previous policy version 2024D0078F.

not FDA approvedRegulatory status

5Randomized trials

n = 576Trial participants

4Non-randomized studies

Coverage Criteria

Not Medically Necessary / Experimental

Not covered when ANY of the following apply

Compounded pellet use: Compounded naltrexone implantable pellets are not FDA approved and are not proven nor medically necessary for any indication.

This policy does not apply to Vivitrol® (extended-release injectable naltrexone).

This policy specifically excludes the FDA-approved extended-release injectable naltrexone product Vivitrol® (naltrexone powder for suspension for injection, extended‑release). The policy also does not apply to HCPCS code J2315, which is the code associated with Vivitrol®; inclusion of other procedure or drug codes in this policy is for reference and does not imply coverage.

Compounded naltrexone implantable pellets are considered not proven and not medically necessary for any indication and are therefore not covered.

Coding

Procedure CPT CodesCPT

11981	Insertion, drug-delivery implant (i.e., bioresorbable, biodegradable, non-biodegradable)
11982	Removal, non-biodegradable drug delivery implant
11983	Removal with reinsertion, non-biodegradable drug delivery implant

Policy Summary

PayerUnitedHealthcare

PolicySubcutaneous Implantable Naltrexone Pellets

Policy CodePolicy 2025D0078G

Change TypeTemplate updateroutine review

Effective DateJan 1, 2025

Next Review Date

Key ActionDo not submit claims for compounded implantable naltrexone pellets as they are considered not proven and not medically necessary and are subject to denial.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

HCPCS / Drug CodesHCPCS

J3490	Unclassified drugs
J7999	Compounded drug, not otherwise classified

Provider Actions and Billing Guidance

Prior Authorization

Prior Authorization and Denial Risk

Prior authorization is not applicable for compounded implantable naltrexone pellets because compounded naltrexone pellets are considered not proven and not medically necessary for any indication. Claims for these products are subject to denial.

Compounded implantable naltrexone pellets are considered not proven and not medically necessary and therefore subject to denial.
This policy does not apply to Vivitrol® (naltrexone powder for suspension for injection, extended-release).

Documentation Required

Coding and Documentation

Use this guidance when preparing claims: include the applicable procedure and drug codes on all claims and support with documentation. Listing of codes in this policy is for reference and does not guarantee coverage or payment. Benefit coverage is determined by the member’s specific benefit plan document and applicable law.

Include applicable procedure codes such as CPT 11981, 11982, 11983 when relevant to implant procedures.
Include applicable HCPCS drug and supply codes such as J3490 (unclassified drugs) and J7999 (compounded drug, not otherwise classified) when billing compounded products.
Do not bill J2315 (Vivitrol®) for compounded pellets — policy does not apply to J2315.

Denial Risk

Denial Risk for Compounded Pellets

Compounded implantable naltrexone pellets billed with procedure or drug codes listed in this policy are considered not proven and not medically necessary. Such claims are at high risk for denial; confirm coverage against the member’s benefit plan before providing or billing for these products.

Claims for compounded naltrexone pellets billed with CPT 11981/11982/11983, or HCPCS J3490/J7999, may be denied as not medically necessary.
Verify member benefits and obtain any required authorizations for covered alternatives prior to service.

Background and Evidence Summary

Compounded subcutaneous naltrexone implantable pellets are non‑FDA‑approved compounded drug products intended to provide extended‑release naltrexone. Systematic reviews and clinical studies have examined naltrexone implants for opioid dependence, but the evidence base is limited in quantity and quality — trials are small, of short duration, and sometimes include overlapping cohorts. Because these implants are compounded and not FDA‑approved, their use is considered experimental or unproven and should be limited to clinical research settings.

Definitions

Compounded naltrexone pellets — definition and status

DefinitionCompounded naltrexone pellets are non‑FDA‑approved, compounded subcutaneous drug pellets intended to provide extended‑release naltrexone.

Regulatory statusNot FDA approved (compounded drugs, including compounded naltrexone pellets).

Coverage stanceNot proven and not medically necessary for any indication; not covered under this policy.

ExclusionPolicy does not apply to Vivitrol® (naltrexone powder for suspension for injection, extended‑release).

Recommended useUse should be limited to clinical trials until better‑designed research establishes safety and efficacy.

Site of Care

Billing Rule

Office billing for implant procedures does not authorize coverage for compounded pellets

Billing or coding for insertion, removal, or reinsertion of a drug-delivery implant (CPT 11981–11983) in the office setting is not authorization of coverage for compounded naltrexone pellets.

Insertion: CPT 11981
Removal: CPT 11982
Removal with reinsertion: CPT 11983

Revision History

2025-07-01routine_review_archivedLatest

Routine review completed and previous policy version 2024D0078F archived.

2025-01-01effective_date

Policy version 2025D0078G became effective and included a template update with revised Benefit Considerations.